VLA-2とは 意味・読み方・使い方

The humanized recombinant anti-VLA-4 antibody molecules having specificity to VLA-4 and an antigen-binding site, wherein at least one of the complementarity determining regions (CDRs) of variable regions is derived from non-humanized recombinant anti-VLA-4 antibody, and the antibody has an efficacy of about 20 to 100% based on the potency of mouse HP1/2 monoclonal antibody.例文帳に追加

ＶＬＡ４に対する特異性及び抗原結合部位を有するヒト化組換え抗体分子であって、可変領域の相補性決定領域（ＣＤＲ）の少なくとも１つが非ヒト抗ＶＬＡ４抗体から導かれ且つ該抗体がマウスＨＰ１／２モノクローナル抗体の効力の約２０〜１００％の効力を有する、上記のヒト化組換え抗体分子。 - 特許庁

The humanized recombinant anti-VLA-4 antibodies has the specificity to VLA4 and antigen-binding sites, wherein at least one of complementarity determining region (CDR) of variable domain is derived from non-humanized anti-VLA-4 antibodies, and the antibody has a potency of about 20 to 100% based on the potency of mouse HP1/2 monoclonal antibody.例文帳に追加

ＶＬＡ４に対する特異性及び抗原結合部位を有するヒト化組換え抗体分子であって、可変領域の相補性決定領域（ＣＤＲ）の少なくとも１つが非ヒト抗ＶＬＡ４抗体から導かれ且つ該抗体がマウスＨＰ１／２モノクローナル抗体の効力の約２０〜１００％の効力を有する、上記のヒト化組換え抗体分子。 - 特許庁

In a humanized recombinant antibody molecule having a specificity and antigen binding site to VLA-4, at least one of the complementarity determining regions (CDRs) of variable domains is derived from a non-human VLA-4 antibody and the antibody has about 20 to 100% effectiveness of HP1/2 murine monoclonal antibody.例文帳に追加

ＶＬＡ４に対する特異性及び抗原結合部位を有するヒト化組換え抗体分子であって、可変領域の相補性決定領域（ＣＤＲ）の少なくとも１つが非ヒト抗ＶＬＡ４抗体から導かれ且つ該抗体がマウスＨＰ１／２モノクローナル抗体の効力の約２０〜１００％の効力を有する、上記のヒト化組換え抗体分子。 - 特許庁